相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DURATION-1 Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
John B. Buse et al.
DIABETES CARE (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Richard M. Bergenstal et al.
LANCET (2010)
Family Practices' Achievement of Diabetes Quality of Care Targets and Risk of Screen-Detected Diabetic Retinopathy
Martin C. Gulliford et al.
PLOS ONE (2010)
Trends in the prevalence and incidence of diabetes in the UK: 1996-2005
E. L. Masso Gonzalez et al.
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH (2009)
Cost-effectiveness of reducing wait times for cataract surgery in Ontario
Robert B. Hopkins et al.
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE (2008)
Screening Uptake in a Well-Established Diabetic Retinopathy Screening Program The role of geographical access and deprivation
Graham P. Leese et al.
DIABETES CARE (2008)
Health utility values associated with diabetic retinopathy
A. Lloyd et al.
DIABETIC MEDICINE (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Clinical Risk Factors, DNA Variants, and the Development of Type 2 Diabetes.
Valeriya Lyssenko et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Utilities and disutilities for type 2 diabetes treatment-related attributes
Louis S. Matza et al.
QUALITY OF LIFE RESEARCH (2007)
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes
Joshua A. Ray et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
The relation between intermittent dosing and adherence: Preliminary insights
Margaret E. Kruk et al.
CLINICAL THERAPEUTICS (2006)
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - A randomized trial
RJ Heine et al.
ANNALS OF INTERNAL MEDICINE (2005)
Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data
A Bagust et al.
HEALTH ECONOMICS (2005)
The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making
AJ Palmer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Validation of the CORE diabetes model against epidemiological and clinical studies
AJ Palmer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments
W Redekop et al.
DIABETES & METABOLISM (2004)
Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis
JB Wasserfallen et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2004)
Global prevalence of diabetes - Estimates for the year 2000 and projections for 2030
S Wild et al.
DIABETES CARE (2004)
The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65)
P Clarke et al.
DIABETIC MEDICINE (2003)
Utilities associated with diabetic retinopathy: results from a Canadian sample
S Sharma et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2003)
Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62)
P Clarke et al.
MEDICAL DECISION MAKING (2002)
Effect of improved glycemic control on health care costs and utilization
EH Wagner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
One thousand health-related quality-of-life estimates
TO Tengs et al.
MEDICAL CARE (2000)
Complications of diabetes: screening for retinopathy and management of foot ulcers
A Melville et al.
QUALITY IN HEALTH CARE (2000)
分享论文
